Jazz Pharmaceuticals launched a $1 billion exchangeable senior notes offering due 2032 through its subsidiary Jazz Investments I Limited. The company also plans to repurchase up to $225 million of its ordinary shares concurrently with the offering pricing.
Jazz Pharmaceuticals launched a $1 billion exchangeable senior notes offering due 2032 and plans to repurchase up to $225 million of its ordinary shares.
The Dublin-based biopharma company said its wholly-owned subsidiary, Jazz Investments I Limited, will sell the notes to qualified institutional buyers under Rule 144A, with net proceeds earmarked for general corporate purposes.
The notes will accrue interest payable semiannually and carry a senior unsecured guarantee from Jazz Pharmaceuticals. Initial purchasers have a 13-day option to buy up to an additional $150 million in notes. The interest rate and initial exchange rate will be set at pricing. Upon exchange, the issuer will pay cash up to the aggregate principal amount, with any excess settled in cash, ordinary shares, or a combination at the issuer's election.
The concurrent share repurchases, priced at the closing price on the offering date, will be funded from existing cash and drawn against the company's share repurchase program announced in July 2024. The buyback could support the share price while the notes offering adds leverage to the balance sheet, with potential dilution if holders convert.
The notes rank senior to future subordinated debt, equal in right of payment to existing unsecured liabilities, and structurally junior to all existing and future indebtedness of Jazz Pharmaceuticals' subsidiaries. The notes and the guarantee will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such debt, and to certain liabilities preferred under Bermuda or Irish law.
Jazz Pharmaceuticals said the repurchases could increase or reduce the size of any decrease in the market price of its ordinary shares, resulting in a higher effective exchange price for the notes. The offering is not contingent on the repurchase of any shares, and the company said it cannot predict the magnitude of market activity or the overall effect on the notes or ordinary share prices.
The company, which trades on Nasdaq under the ticker JAZZ, develops therapies for rare diseases, epilepsies, cancers, and sleep disorders. Its portfolio includes leading treatments across these areas, with a pipeline focused on rare disease therapeutics. The percentage of outstanding shares covered by the repurchase program has not yet been disclosed.
The dual transaction gives Jazz Pharmaceuticals fresh capital while returning cash to shareholders, a structure that could dilute existing holders if the notes convert. Investors will watch the pricing terms, including the interest rate and exchange premium, for signals on the company's cost of capital.
This article is for informational purposes only and does not constitute investment advice.
